NATHBIOGEN

- SEBI has initiated a forensic audit of Nath Bio-Genes (I) Ltd. - Forensic Auditor: CNK & Associates LLP. - The audit will cover financial years 2020-21 to 2025-26. - The Company is extending full cooperation to the Forensic Auditor.

- Investor Presentation for Unaudited Financial Results for Q1 FY27 (period ended June 30, 2026). - Highlights competitive positioning, focus on cotton, wheat, maize & fodder bajra, and strong R&D. - Mentions historical revenue growth of 12.5% CAGR from FY19 to FY26 (INR 1,917 Mn to INR 4,316 Mn). - Emphasizes shareholder value creation through business growth and margin expansion.

- Consolidated Revenue ₹328.40 Cr vs ₹283.70 Cr (▲15.77% YoY) - EBITDA ₹34.15 Cr vs ₹28.31 Cr (▲20.62% YoY) - PAT ₹32.26 Cr vs ₹28.28 Cr (▲14.07% YoY) - EBITDA Margin 10.39% vs 9.98% (▲41bps) - The 33rd Annual General Meeting will be held on Thursday, September 24, 2026, at 11:00 a.m. via video conference.

- Trading window closed from July 01, 2026, until 48 hours after the declaration of Unaudited Financial Results for the quarter ended June 30, 2026. - The date of the Board Meeting for results declaration will be intimated separately.

Management expressed excitement for FY27, citing a robust pipeline of new varieties across cotton, paddy, maize, and vegetables. The company plans to continue investing in R&D, expanding its distribution network, deepening farmer engagement, and pursuing international growth with rigor, aiming to replicate the Uzbekistan joint venture model in other geographies. The Indian seed market is expected to grow at a 12-14% CAGR over the next five years, driven by agricultural modernization and increasing seed replacement rates. FY26 saw purposeful growth, with strong performance in cotton, 35% YoY paddy value growth, and maize volumes surging 54% YoY with 78% value growth.

Nath Bio-Genes (I) Ltd. submitted the audio recording of its conference call held on May 5, 2026, at 4:00 PM. The call discussed the audited financial results for the quarter and year ended March 31, 2026. The recording is accessible on the company's website.

Nath Bio-Genes (I) Ltd. released its Investor Presentation for Q4 & FY26. The company reported a 12.5% Revenue CAGR from FY19 (INR 1,917 Mn) to FY26 (INR 4,316 Mn). Average Selling Price (ASP) for Field Crops increased from 128 Rs/kg in FY18 to 480 Rs/kg in FY26, and for Vegetables from 293 Rs/kg to 1,244 Rs/kg over the same period, highlighting strong growth in key operational metrics.

Nath Bio-Genes (I) Ltd.'s Board of Directors, at its meeting on May 04, 2026, recommended a dividend of ₹2.00 per equity share (20%) for FY 2025-26. The board also approved the reappointment of Mr. Hitesh Rajnikant Purohit as an Independent Director for a second term of five years and an increase in the Managing Director's remuneration from ₹66 lakhs to ₹144 lakhs per annum, effective January 01, 2026. Additionally, M/s K.P. Sahasrabudhe & Co. were appointed as internal auditors for FY 2026-27.